Gravity by Alpha Nodus Automates 80 Percent of Authorizations Within Seconds
SUNRISE, Fla., June 20, 2023 (Newswire…
The post AI-Powered Pre-Authorization Advances Administrative Efficiency in Radiology first appeared on Enrose Magazine.
BALA-CYNWYD, Pa., June 20, 2023 (Newswire.com)
–
Connect America, a nationally recognized innovator in virtual connective care solutions in the home that enable older adults and those living with chronic conditions to live safe and well, announced today that it was recognized as a Top Company in Remote Patient Monitoring upon conclusion of extensive research and company outreach by AVIA Marketplace, the leading digital health marketplace.
The Connect America Home™ platform, which includes their RPM solution powered by 100Plus, enables healthcare providers to deliver better care for patients in the comfort of their homes while remotely managing their chronic conditions. In addition to remote monitoring services, the company’s complete end-to-end platform includes the AI-enabled Esper virtual health assistant™ and clinical insights and analytics that help power more informed decision-making, earlier interventions, and better care and outcomes.
“We are honored to be acknowledged as one of the leading Remote Patient Monitoring companies by AVIA,” said Janet Dillione, CEO of Connect America. “With the rising need for remote monitoring, the 100Plus RPM solution was introduced with an explicit goal of reducing patient, clinician, and health care system barriers to RPM use and to improve health and cost outcomes. Today, we are proud that 69% of providers using our 100Plus RPM solution believe it has reduced or greatly reduced the incidence of hospitalizations and other forms of high acuity care, and it consistently drives a 92% customer satisfaction rate while improving clinical efficiencies. “
The Top Remote Patient Monitoring Companies Report represents the aggregation and analysis of client ratings and reviews as well as health system implementation data across the country and highlights broader industry trends to contextualize the impact the companies and products are currently having in the space. Given the complexity and evolving nature of remote patient monitoring, the 2023 refresh of this report helps define the remote patient monitoring landscape and how these solutions best support patient care.
“With the rise of Remote Patient Monitoring solutions, a transformative shift in patient care is imminent. Our report illuminates the trailblazers making significant strides in this field,” said Dhiraj Patkar, SVP of Digital Health Solutions at AVIA. “Our objective with the Top Remote Patient Monitoring Companies Report is to arm healthcare organizations with comprehensive insights and tools crucial for the successful deployment and expansion of these advanced digital solutions. Leveraging digital technologies, we can extend care access, optimize patient experiences and outcomes, and tackle the escalating challenges that healthcare providers encounter in today’s multifaceted landscape.”
###
AVIA Marketplace is where innovative health systems and hospitals go to find the right digital health solutions. It’s built to efficiently search vendors and guide informed decisions, with tools like product comparisons, match scores, report generators, peer reviews, and market insights.
Access the full report findings from AVIA Marketplace’s Top Remote Patient Monitoring Companies list here.
About Connect America
Connect America, and its family of brands, is the leading provider of connective health solutions dedicated to empowering aging adults and vulnerable populations to live safely and independently at home for as long as possible. The company’s AI-assisted digital health and safety platform includes Remote Patient Monitoring (RPM) solutions, Personal Emergency Response Services (PERS), Medication Management, Analytics, and SDoH support that enables continuous in-home and mobile monitoring of aging and at-risk populations for more timely interventions and smart escalations of care. With improved outcomes, reduced hospitalizations and lower care costs, patients and their care circles have peace of mind knowing Connect America is how health and home connect. To learn more, visit https://www.connectamerica.com.
Contact Information:
Sean Chase
AVIA Press Contact
(603) 307-9428
Jane MacPherson
Communications Manager
16473027164
Original Source:
Connect America Named to AVIA Marketplace’s Top Remote Patient Monitoring Companies
The post Connect America Named to AVIA Marketplace’s Top Remote Patient Monitoring Companies first appeared on Enrose Magazine.
LVDDS adds the digitally designed, 3D-printed Comfort3D Bite Splint to its family of preventive care appliances.
LVDDS Introduces the Comfort3D\u21…
The post LVDDS Introduces the Comfort3D (TM) Bite Splint first appeared on Enrose Magazine.
Medicare-Covered SCS Trials Can Be a Game-Changer for Patients Who Haven’t Found Relief With Conventional Treatments
METAIRIE, La., June 19, 2023 (Newswire.com)
–
Lonseth Interventional Pain Centers, a renowned provider of pain management solutions, proudly announces the offering of Spinal Cord Stimulator (SCS) Trials for individuals affected by chronic pain conditions, including Diabetic Peripheral Neuropathy. These Medicare-covered trials are a game-changing recourse for patients who haven’t found sufficient relief from conventional treatments.
SCS Trials involve the temporary implantation of a device that emits low-level electrical signals to the spinal cord or specific nerves, effectively blocking the transmission of pain signals to the brain. This outpatient procedure, conducted under the guidance of trained professionals, allows patients to experience the potential benefits of SCS without committing to a permanent implantation.
The trial period lasts about a week. After which, patients and their physicians evaluate the effectiveness of the treatment. Successful trials, typically marked by a significant reduction in pain, may lead to the patient becoming a candidate for permanent SCS implantation.
SCS is a progressive therapy involving a device that sends mild electrical currents to the spinal cord, mitigating chronic pain. This technique is particularly useful after conventional non-surgical treatments have proven insufficient. It is programmable to target specific pain areas, making it an effective option for various chronic pain conditions.
During an SCS trial, patients can expect careful preparation, expert execution of the procedure, and a personalized adjustment process to ensure optimal pain control. After the procedure, they take home the trial stimulator for several days to assess its effectiveness in their daily lives.
Candidates for these Medicare-covered SCS trials typically include those with chronic pain impacting daily activities who have not found relief from other treatments, who do not suffer from untreated drug addiction, and who have successfully managed any underlying psychiatric conditions. Moreover, patients should be healthy enough to undergo the procedure safely.
Lonseth Interventional Pain Centers is pleased to confirm that these revolutionary SCS trials are Medicare-covered. Its dedicated team stands ready to support patients through each phase, providing them with a comforting, informed experience.
People don’t have to let chronic pain rule their life. They can begin a journey toward less pain by reaching out to Lonseth Interventional Pain Centers to schedule a consultation and find out if they qualify for SCS trials. This groundbreaking therapy could be the key to a new, less painful chapter of their life.
Contact Information:
Eric Lonseth
Doctor
(504) 732-1094
Original Source:
Lonseth Interventional Pain Centers Launches Spinal Cord Stimulator Trials for Diabetic Peripheral Neuropathy
The post Lonseth Interventional Pain Centers Launches Spinal Cord Stimulator Trials for Diabetic Peripheral Neuropathy first appeared on Enrose Magazine.
GERMANTOWN, Md., June 16, 2023 (Newswire.com)
–
Seraxis today announced late-breaking results of an ongoing study evaluating the efficacy of SRE pancreat…
The post Late-Breaking Results of a Preclinical Efficacy Study Presented at ENDO 2023 Show Seraxis SRE Sustainably Reverses Type-1-Diabetes Hyperglycemia first appeared on Enrose Magazine.
GERMANTOWN, Md., June 16, 2023 (Newswire.com)
–
Seraxis today announced late-breaking results of an ongoing study evaluating the efficacy of SRE pancreat…
The post Late-Breaking Results of a Preclinical Efficacy Study Presented at ENDO 2023 Show Seraxis SRE Sustainably Reverses Type-1-Diabetes Hyperglycemia first appeared on Enrose Magazine.
New Virtual Mental Health and Substance Use (MHSU) Program From Compass Health Center Delivers Specialized Care to a Broader Audience, Bridging the Gap in Access to Essential Services
…
The post Compass Health Center Introduces Virtual Program to Improve Access to Mental Health and Substance Use Treatment for Young Adults and Adults first appeared on Enrose Magazine.
KANSAS CITY, Mo., June 15, 2023 (Newswire.com)
–
Dr. Irfan Handoo, a leading expert in psychiatry and renowned provider of transcranial magnetic stimulation (TMS) and IV ketamine treatments, is excited to announce the relocation of his clinic to a new state-of-the-art facility. The clinic has recently signed a lease and will move into a spacious 4,000-square-foot location at 7011 West 121st Street, Suite 105, Overland Park, KS 66209, on Monday, June 19.
This move marks a significant milestone for Dr. Handoo and his team as they continue their commitment to providing exceptional care and expanding access to cutting-edge treatments for patients struggling with mental health conditions. The new facility offers an environment designed to foster comfort and healing, providing a welcoming space for patients seeking TMS and IV ketamine treatments.
“We are thrilled to announce our upcoming move to Overland Park,” said Dr. Handoo. “This new clinic will allow us to serve our patients better, providing them with a modern and compassionate environment where they can continue to receive the high standards of care they have come to expect from us. Our goal is to create a nurturing space that complements the innovative treatments we offer, enabling our patients to find relief and improve their overall well-being.”
Deep TMS therapy, a noninvasive procedure that uses magnetic fields to stimulate targeted areas of the brain, has shown promising results in the treatment of treatment-resistant depression. IV ketamine treatments have also emerged as a breakthrough therapy for individuals who have not found relief from traditional treatments. Dr. Handoo’s expertise in administering these treatments, coupled with the new facility’s advanced capabilities, ensures that patients will receive the highest quality care in a comfortable and modern setting.
The new location boasts ample space for treatment rooms, cutting-edge equipment, and a welcoming reception area. Dr. Handoo and his team have meticulously designed the clinic to provide a serene and supportive atmosphere where patients can feel at ease throughout their treatment journey. The move to Overland Park represents a significant investment in the community and reaffirms Dr. Handoo’s commitment to improving mental health care in the region.
Patients seeking Deep TMS and IV ketamine treatments can schedule appointments at the new location starting Monday, June 19. Dr. Handoo and his team look forward to welcoming both existing and new patients to experience the enhanced care and comfort provided by the new clinic.
For more information about Dr. Irfan Handoo and his practice, please visit https://drhandoo.com/ or contact 816-441-9875.
Contact Information:
Dr. Irfan Handoo
816-441-9875
Original Source:
Kansas City’s Largest TMS and IV Ketamine Clinic Moving to Overland Park
The post Kansas City’s Largest TMS and IV Ketamine Clinic Moving to Overland Park first appeared on Enrose Magazine.
Beginning in the second quarter of 2023, NIT will provide Actinium-225 in millicurie quantities, marking a significant step forward in cancer treatment
DALLAS, June 15, 2023 (Newswire.com)
–
Nano Imrad Technology (NIT), an innovative medical research and development company, is pleased to announce the availability of Actinium-225 for medical research and treatment. Beginning in the second quarter of 2023, NIT will provide Actinium-225 in millicurie quantities, marking a significant step forward in cancer treatment.
With the capacity to produce significant quantities of Actinium-225 daily, NIT is not only making this precious element more accessible, but is also contributing significantly to the global fight against cancer.
Actinium-225, a radioactive element, is gaining recognition in the medical community for its potential in targeted alpha therapy for cancer treatment. Its ability to deliver precise radiation directly to cancer cells, while leaving healthy tissue unaffected, has shown promise in shrinking and even eliminating tumors.
NIT has developed a breakthrough method to produce Actinium-225 in a reliable, safe, and cost-effective manner, overcoming traditional challenges associated with the production and acquisition of this element. This pioneering approach enhances access to Actinium-225, empowering researchers, clinicians, and patients to benefit from cutting-edge treatments and technologies.
NIT’s Actinium-225 will be available to licensed researchers, research institutions, and clinicians, who can utilize this crucial element for research and treatments. Actinium-225 is available only to organizations and individuals with a verified Radioactive Materials (RAM) License.
For more information about NIT and Actinium-225, please visit https://nitresearch.com.
About Nano Imrad Technology (NIT)
NIT is a medical research and development company specializing in the production of diagnostic imaging and therapeutic medical isotopes. Their core technology focuses on immune-labeled radionuclide nanoparticles, and their mission is to make Actinium-225 widely available for research and treatment purposes, revolutionizing the landscape of cancer treatment.
Contact Information:
Ed O’Connor
Director of Sales
+1 (332) 213-9516
Original Source:
Nano Imrad Technology (NIT) Announces Availability of Actinium-225, Pioneering a New Era of Cancer Treatment
The post Nano Imrad Technology (NIT) Announces Availability of Actinium-225, Pioneering a New Era of Cancer Treatment first appeared on Enrose Magazine.
Release of Fortifeye Healthy Weight Loss Bundle
Dr. Michael Lange Dr. Michael Lange empowers many on healthy weight loss
…
The post Fortifeye Vitamins and Dr. Michael Lange Empower Global Audience with Effective Strategies for Healthy Weight Loss first appeared on Enrose Magazine.
Copyright © 2024 | WordPress Theme by MH Themes
